Drug: Trimethoprim-Sulfamethoxazole 160

Phase 2Small molecule

Drug: Trimethoprim-Sulfamethoxazole 160 is one of 42 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Kidney InjuryActive, not recruiting

Acute Kidney InjuryPhase 2

Active, not recruiting

Competition

Competitive Landscape

178 competitors in Acute Kidney Injury

#DrugCompanyPhaseTrials

Truphylline

TThe Searle Company Limited Pakistan

Phase 3

2 2

Nicotinamide Treatment

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 3

NORADRENALIN

UUniversity of Aarhus

Phase 3

1 4

IRBESARTAN,

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 5

Crestor

AstraZeneca

Preclinical

3 6

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 7

Celexa

AbbVie

Preclinical

1 8

Proamatine

Takeda

Preclinical

1 9

Lexapro

AbbVie

Preclinical

1 10

Lescol

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Acute Kidney Injury

NCT07224997

Clinical

Trials by Indication[1]

Acute Kidney Injury1 trial

Trimethoprim-Sulfamethoxazole (TMP/SMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections

Not yet recruiting·HHospital Civil de Guadalajara·Phase 2·NCT07224997·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: Trimethoprim-Sulfamethoxazole 160. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug: Trimethoprim-Sulfamethoxazole 160 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug: Trimethoprim-Sulfamethoxazole 160. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Civil de Guadalajara company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHospital Civil de Guadalajara

Drug: Trimethoprim-Sulfamethoxazole 160

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Acute Kidney Injury1 trial

References

Drug Info

Quick Facts

Related News